Summary
A Framework Partnership Agreement (FPA) between the Coalition for Epidemic Preparedness Innovations (CEPI) and the European Union (EU) was signed in April 2019, to finance and coordinate the development of new medical countermeasures to prevent and contain infectious disease epidemics, which are of particular concern to low- and middle-income countries. As part of the FPA, a call for proposals (CfP) was launched jointly with the EU and supported the preclinical development of Rift Valley Fever Virus vaccines and the late-stage development of Chikungunya virus vaccines (CHIKV). While previous funding has led to the development of pre-licensure CHIK vaccines, in this current application we like to further advance our CHIK vaccine programme, and support CHIK vaccines that are near or have achieved regulatory licensure by supporting their clinical development into phase IV clinical trials to increase our understanding of the long-term safety, durability of protection, and effectiveness against virologically confirmed disease. Furthermore, we would like to expand the use indication by supporting clinical trials in vulnerable populations, including children, immunosuppressed and pregnant women.
As part of this grant application, we also like to launch a CfP on Controlled Human Infection Models (CHIM). The overall objective of the CHIM proposal is to support research projects that increase knowledge in vaccine-induced mucosal immunity and advance the development of transmission-blocking vaccines against coronaviruses and other potential respiratory viral threats. The expected outcome of this CfP is to create a global network of experts conducting CHIM at a high level of consistency and reliability.
This current grant application seeks to leverage €70M from Horizon Europe, which will be supplemented with €30M from CEPI making a pool of €100M. Awards will have a 36–48-month duration and will be administered by the CEPI secretariat.
As part of this grant application, we also like to launch a CfP on Controlled Human Infection Models (CHIM). The overall objective of the CHIM proposal is to support research projects that increase knowledge in vaccine-induced mucosal immunity and advance the development of transmission-blocking vaccines against coronaviruses and other potential respiratory viral threats. The expected outcome of this CfP is to create a global network of experts conducting CHIM at a high level of consistency and reliability.
This current grant application seeks to leverage €70M from Horizon Europe, which will be supplemented with €30M from CEPI making a pool of €100M. Awards will have a 36–48-month duration and will be administered by the CEPI secretariat.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101126531 |
| Start date: | 01-06-2023 |
| End date: | 30-11-2028 |
| Total budget - Public funding: | 100 000 000,00 Euro - 70 000 000,00 Euro |
Cordis data
Original description
A Framework Partnership Agreement (FPA) between the Coalition for Epidemic Preparedness Innovations (CEPI) and the European Union (EU) was signed in April 2019, to finance and coordinate the development of new medical countermeasures to prevent and contain infectious disease epidemics, which are of particular concern to low- and middle-income countries. As part of the FPA, a call for proposals (CfP) was launched jointly with the EU and supported the preclinical development of Rift Valley Fever Virus vaccines and the late-stage development of Chikungunya virus vaccines (CHIKV). While previous funding has led to the development of pre-licensure CHIK vaccines, in this current application we like to further advance our CHIK vaccine programme, and support CHIK vaccines that are near or have achieved regulatory licensure by supporting their clinical development into phase IV clinical trials to increase our understanding of the long-term safety, durability of protection, and effectiveness against virologically confirmed disease. Furthermore, we would like to expand the use indication by supporting clinical trials in vulnerable populations, including children, immunosuppressed and pregnant women.As part of this grant application, we also like to launch a CfP on Controlled Human Infection Models (CHIM). The overall objective of the CHIM proposal is to support research projects that increase knowledge in vaccine-induced mucosal immunity and advance the development of transmission-blocking vaccines against coronaviruses and other potential respiratory viral threats. The expected outcome of this CfP is to create a global network of experts conducting CHIM at a high level of consistency and reliability.
This current grant application seeks to leverage €70M from Horizon Europe, which will be supplemented with €30M from CEPI making a pool of €100M. Awards will have a 36–48-month duration and will be administered by the CEPI secretariat.
Status
SIGNEDCall topic
HORIZON-HLTH-2022-CEPI-15-01-IBAUpdate Date
12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
